3-year follow-up of the NIMH MTA study
- PMID: 17667478
- DOI: 10.1097/CHI.0b013e3180686d48
3-year follow-up of the NIMH MTA study
Abstract
Objective: In the intent-to-treat analysis of the Multimodal Treatment Study of Children With ADHD (MTA), the effects of medication management (MedMgt), behavior therapy (Beh), their combination (Comb), and usual community care (CC) differed at 14 and 24 months due to superiority of treatments that used the MTA medication algorithm (Comb+MedMgt) over those that did not (Beh+CC). This report examines 36-month outcomes, 2 years after treatment by the study ended.
Method: For primary outcome measures (attention-deficit/hyperactivity disorder [ADHD] and oppositional defiant disorder [ODD] symptoms, social skills, reading scores, impairment, and diagnostic status), mixed-effects regression models and orthogonal contrasts examined 36-month outcomes.
Results: At 3 years, 485 of the original 579 subjects (83.8%) participated in the follow-up, now at ages 10 to 13 years, (mean 11.9 years). In contrast to the significant advantage of MedMgt+Comb over Beh+CC for ADHD symptoms at 14 and 24 months, treatment groups did not differ significantly on any measure at 36 months. The percentage of children taking medication >50% of the time changed between 14 and 36 months across the initial treatment groups: Beh significantly increased (14% to 45%), MedMed+Comb significantly decreased (91% to 71%), and CC remained constant (60%-62%). Regardless of their treatment use changes, all of the groups showed symptom improvement over baseline. Notably, initial symptom severity, sex (male), comorbidity, public assistance, and parental psychopathology (ADHD) did not moderate children's 36-month treatment responses, but these factors predicted worse outcomes over 36 months, regardless of original treatment assignment.
Conclusions: By 36 months, the earlier advantage of having had 14 months of the medication algorithm was no longer apparent, possibly due to age-related decline in ADHD symptoms, changes in medication management intensity, starting or stopping medications altogether, or other factors not yet evaluated.
Similar articles
-
National Institute of Mental Health Multimodal Treatment Study of ADHD follow-up: 24-month outcomes of treatment strategies for attention-deficit/hyperactivity disorder.Pediatrics. 2004 Apr;113(4):754-61. doi: 10.1542/peds.113.4.754. Pediatrics. 2004. PMID: 15060224 Clinical Trial.
-
Findings from the NIMH Multimodal Treatment Study of ADHD (MTA): implications and applications for primary care providers.J Dev Behav Pediatr. 2001 Feb;22(1):60-73. doi: 10.1097/00004703-200102000-00008. J Dev Behav Pediatr. 2001. PMID: 11265923 Clinical Trial.
-
Clinical relevance of the primary findings of the MTA: success rates based on severity of ADHD and ODD symptoms at the end of treatment.J Am Acad Child Adolesc Psychiatry. 2001 Feb;40(2):168-79. doi: 10.1097/00004583-200102000-00011. J Am Acad Child Adolesc Psychiatry. 2001. PMID: 11211365
-
Evidence, interpretation, and qualification from multiple reports of long-term outcomes in the Multimodal Treatment Study of children with ADHD (MTA): Part II: supporting details.J Atten Disord. 2008 Jul;12(1):15-43. doi: 10.1177/1087054708319525. J Atten Disord. 2008. PMID: 18573924
-
Evidence, interpretation, and qualification from multiple reports of long-term outcomes in the Multimodal Treatment study of Children With ADHD (MTA): part I: executive summary.J Atten Disord. 2008 Jul;12(1):4-14. doi: 10.1177/1087054708319345. J Atten Disord. 2008. PMID: 18573923
Cited by
-
Attention-deficit/hyperactivity disorder Under Treatment Outcomes Research (AUTOR): a European observational study in pediatric subjects.Atten Defic Hyperact Disord. 2015 Dec;7(4):295-311. doi: 10.1007/s12402-015-0177-y. Epub 2015 Jun 27. Atten Defic Hyperact Disord. 2015. PMID: 26115621 Free PMC article.
-
ADGRL3 (LPHN3) variants are associated with a refined phenotype of ADHD in the MTA study.Mol Genet Genomic Med. 2016 Jul 18;4(5):540-7. doi: 10.1002/mgg3.230. eCollection 2016 Sep. Mol Genet Genomic Med. 2016. PMID: 27652281 Free PMC article.
-
Attention deficit hyperactivity disorder (ADHD): review for primary care clinicians.London J Prim Care (Abingdon). 2010 Jul;3(1):45-51. doi: 10.1080/17571472.2010.11493296. London J Prim Care (Abingdon). 2010. PMID: 25949618 Free PMC article.
-
Non-pharmacological interventions for attention-deficit hyperactivity disorder in children and adolescents.Lancet Child Adolesc Health. 2023 Jun;7(6):415-428. doi: 10.1016/S2352-4642(22)00381-9. Epub 2023 Mar 9. Lancet Child Adolesc Health. 2023. PMID: 36907194 Free PMC article. Review.
-
Association between Attention Deficit Hyperactivity Disorder Medication and Depression: A 10-year Follow-up Self-controlled Case Study.Clin Psychopharmacol Neurosci. 2022 May 31;20(2):320-329. doi: 10.9758/cpn.2022.20.2.320. Clin Psychopharmacol Neurosci. 2022. PMID: 35466103 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical